dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Hernández Pascual, Cristina |
dc.contributor.author | Bogdanov Baruj, Patricia |
dc.contributor.author | Gómez-Guerrero, Carmen |
dc.contributor.author | Sampedro Vida, Joel |
dc.contributor.author | Solà Adell, Cristina |
dc.contributor.author | Espejo Ruiz, Carmen |
dc.contributor.author | García Ramírez, Marta |
dc.contributor.author | Simó Canonge, Rafael |
dc.date.accessioned | 2020-02-04T13:37:12Z |
dc.date.available | 2020-02-04T13:37:12Z |
dc.date.issued | 2019-07-24 |
dc.identifier.citation | Hernández C, Bogdanov P, Gómez-Guerrero C, Sampedro J, Solà-Adell C, Espejo C, et al. SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Int J Mol Sci. 2019 Jul 24;20(15):3615. |
dc.identifier.issn | 1422-0067 |
dc.identifier.uri | https://hdl.handle.net/11351/4586 |
dc.description | Diabetic retinopathy; Neuroinflammation; Suppressors of cytokine signaling |
dc.description.abstract | Current treatments for diabetic retinopathy (DR) target late stages when vision has already been significantly affected. Accumulating evidence suggests that neuroinflammation plays a major role in the pathogenesis of DR, resulting in the disruption of the blood-retinal barrier. Suppressors of cytokine signaling (SOCS) are cytokine-inducible proteins that function as a negative feedback loop regulating cytokine responses. On this basis, the aim of the present study was to evaluate the effect of a SOCS1-derived peptide administered by eye drops (2 weeks) on retinal neuroinflammation and early microvascular abnormalities in a db/db mouse model. In brief, we found that SOCS1-derived peptide significantly reduced glial activation and neural apoptosis induced by diabetes, as well as retinal levels of proinflammatory cytokines. Moreover, a significant improvement of electroretinogram parameters was observed, thus revealing a clear impact of the histological findings on global retinal function. Finally, SOCS1-derived peptide prevented the disruption of the blood-retinal barrier. Overall, our results suggest that topical administration of SOCS1-derived peptide is effective in preventing retinal neuroinflammation and early microvascular impairment. These findings could open up a new strategy for the treatment of early stages of DR. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | International Journal of Molecular Sciences;20(15) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Retinopatia diabètica |
dc.subject | Quimiocines |
dc.subject | Retina - Vasos sanguinis |
dc.subject.mesh | Diabetic Retinopathy |
dc.subject.mesh | Suppressor of Cytokine Signaling Proteins |
dc.subject.mesh | Blood-Retinal Barrier |
dc.title | SOCS1-derived peptide administered by eye drops prevents retinal neuroinflammation and vascular leakage in experimental diabetes |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/ijms20153615 |
dc.subject.decs | retinopatía diabética |
dc.subject.decs | proteínas supresoras de la señalización de citocinas |
dc.subject.decs | barrera hematorretinal |
dc.relation.publishversion | https://www.mdpi.com/1422-0067/20/15/3615 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Hernández C, Bogdanov P, Sampedro J, Solà-Adell C, García-Ramírez M, Simó R] Grup de Diabetis i Metabolisme, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Gómez-Guerrero C] Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Renal, Vascular and Diabetes Research Lab, Instituto de Investigacion Sanitaria-Fundación Jimenez Diaz (IIS-FJD), Madrid, Spain. Autonoma University of Madrid (UAM), Madrid, Spain. [Espejo, C] Recerca en Neuroimmunologia clínica, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. |
dc.identifier.pmid | 31344857 |
dc.identifier.wos | 000482383000008 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |